abstract: UNASSIGNED: Severely symptomatic @entity1 with @entity1121 (HC) may benefit from surgical myectomy. In @entity1 with enlarged mitral leaflets and @entity339 , myectomy can be combined with anterior mitral leaflet extension (AMLE) to stiffen the midsegment of the leaflet. The aim of this study was to evaluate the long-term results of myectomy combined with AMLE in @entity1 with obstructive HC. This prospective, observational, single-center cohort study included 98 @entity1 (49    14  years, 37% female) who underwent myectomy combined with AMLE from 1991 to 2012. End points included all-cause mortality and change in clinical and echocardiographic characteristics. Mortality was compared with age- and gender-matched @entity1 with nonobstructive HC and subjects from the general population. Long-term follow-up was 8.3    6.1  years. There was no operative mortality, and New York Heart Association class was reduced from 2.8    0.5 to 1.3    0.5 (p <0.001), left ventricular outflow tract gradient from 93    25 to 9    8  mm Hg (p <0.001), @entity339 from grade 2.0    0.9 to 0.5    0.8 (p <0.001), and systolic anterior motion of the mitral valve from grade 2.4    0.9 to 0.1    0.3 (p <0.001). The 1-, 5-, 10-, and 15-year cumulative survival rates were 98%, 92%, 86%, and 83%, respectively, and did not differ from the general population (99%, 97%, 92%, and 85%, respectively, p  = 0.3) or @entity1 with nonobstructive HC (98%, 97%, 88%, and 83%, respectively, p  = 0.8). In conclusion, in selected @entity1 with obstructive HC, myectomy combined with AMLE is a low-risk surgical procedure. It results in long-term symptom relief and survival similar to the general population.

title: Long-Term Benefit of Myectomy and Anterior Mitral Leaflet Extension in Obstructive XXXX .

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['obstructive hypertrophic cardiomyopathy']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['mitral valve regurgitation', 'mitral regurgitation']

answer: @entity1121 :: (MESH:D002312,Disease) :: ['Hypertrophic Cardiomyopathy']


abstract: OBJECTIVE: The floating wire technique is a special technique for solving interventional problems in aorta- ostial lesions. There are no long-term data in the literature for the floating wire technique in @entity75 . METHODS: One hundred twenty six @entity1 were retrospectively analyzed in this study. All of these @entity1 had a critical @entity301 . The floating wire technique was performed on 64 @entity1 , and the single wire technique was performed on 62 @entity1 . The two groups were compared with each other in terms of lesional and procedural properties. Additionally, 1-year clinical follow-up results were compared between the two groups. RESULTS: There was no significant difference in terms of lesion properties between the groups. In the floating wire group, mean stent length, number of stents, mean procedure time, mean contrast volume, and mean fluoroscopy time were significantly lower than in the single wire group. At 1 year, 1 @entity1 from each group had @entity583 , and no mortality was observed. In the floating wire group, the number of @entity1 who experienced @entity951 and the @entity75 revascularization rate were both significantly lower than in the single wire group. CONCLUSION: The floating wire technique in right @entity301 provides a significant advantage over the single wire technique according to procedural and clinical follow-up results.

title: Comparison of floating wire and single wire techniques in right XXXX in terms of procedural features and one-year clinical follow-up results.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary ostial lesions', 'right coronary aorto-ostial lesion']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion', 'right aorto-ostial lesions']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity301 :: (MESH:D003327,Disease) :: ['coronary ostial lesions']


abstract: BACKGROUND: Described by Theodore Leber in 1916, this syndrome is characterized by unilateral @entity227 , @entity4 and a stellate pattern of exudative deposits in the macula. MATERIAL AND METHODS: Two young adults were examined for sudden unilateral @entity227 preceded by @entity683 . Fundus examination revealed a swollen @entity1781 and a macular star, visualized on @entity941 angiography. Visual field, laboratory tests and cranial and orbital tomodensitometry were performed. RESULTS: Visual field examination showed a centrocecal @entity1019 . Laboratory tests showed @entity32 in one case. Serology testing ( @entity2926 , @entity11102 , @entity3252 and syphilis, etc.) were negative. Tomodensitometry of the brain and orbits gave normal results. One of the @entity1 was treated with intravenous @entity134 boluses; the other received no treatment. A few weeks after the beginning of symptoms, the swelling of the @entity1781 seemed to have declined, leaving the macular star unchanged. CONCLUSION: These two cases typically describe Leber's @entity2479 . The prognosis for visual recovery is usually reported to be excellent, but visual sequelae have been described.

title: [Leber's XXXX : about two cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory syndrome']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual loss']

entities_list: @entity2926 :: ('MESH:D007922', 'Disease') :: ['leptospirosis']

entities_list: @entity2479 :: ('MESH:D012173', 'Disease') :: ['idiopathic stellate neuroretinitis']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['optic disc swelling']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['a flu-like syndrome']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity1781 :: ('MESH:D009901', 'Disease') :: ['optic disc']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

entities_list: @entity11102 :: ('MESH:D002372', 'Disease') :: ['cat scratch disease']

entities_list: @entity3252 :: ('MESH:D014123', 'Disease') :: ['toxoplasmosis']

answer: @entity2479 :: (MESH:D012173,Disease) :: ['idiopathic stellate neuroretinitis']


abstract: PURPOSE OF THE STUDY: @entity78 ceramics are synthetic bone substitutes able to fill in @entity79 as a support of the bone growth. This work consisted in an in vitro assessment of osteoblasts and fibroblasts cultures on macroporous @entity460 - @entity1391 bone substitutes to analyze the interaction between cells and bone substitute. MATERIALS AND METHODS: The macroporous ceramic was composed of 70% @entity692 and 30% @entity9039 with known mechanical and physico-chemical properties. Three compounds were processed with different size of macropore and with or without microporosity on their surface. Cells were seeded on discs measuring 10 mm in diameter and 2 mm in thickness. Cellular viability was evaluated by the @entity98 test for every stage of observation. An histological study to observe the invasion in the depth of discs was performed. Scanning electron microscopy was used to analyze the cellular comportment in contact with the surface of substitutes. RESULTS: An exponential cellular growth was effective on each substitute with the two cellular types. Cells spread on the surface of the compounds covering macropores and colonized the depth of the discs. A size of macropore of 300 microm or more seemed to support this invasion. 15 microm sized interconnections appeared to be effective to allow cell migration between macropores. The cell proliferation was similar on substitutes with or without microporosity. CONCLUSION: Biomaterials currently used as bone substitute are more or less osteoconductive but they have no osteoinductive property. A hybrid association of @entity78 ceramic with osteogenic cells should promote the development of a @entity78 compound with osteoinductive capacity.

title: [Cellular culture of osteoblasts and fibroblasts on porous @entity460 - XXXX bone substitutes].

entities_list: @entity9039 :: ('MESH:C018392', 'Chemical') :: ['tri-calcium phosphate']

entities_list: @entity78 :: ('MESH:C020243', 'Chemical') :: ['calcium phosphate', 'calcium-phosphate', 'Calcium phosphate']

entities_list: @entity692 :: ('MESH:D017886', 'Chemical') :: ['hydroxyapatite']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone destruction']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity1391 :: (CHEBI:26020,Chemical) :: ['phosphate']


abstract: PURPOSE OF THE STUDY: @entity78 ceramics are synthetic bone substitutes able to fill in @entity79 as a support of the bone growth. This work consisted in an in vitro assessment of osteoblasts and fibroblasts cultures on macroporous @entity460 - @entity1391 bone substitutes to analyze the interaction between cells and bone substitute. MATERIALS AND METHODS: The macroporous ceramic was composed of 70% @entity692 and 30% @entity9039 with known mechanical and physico-chemical properties. Three compounds were processed with different size of macropore and with or without microporosity on their surface. Cells were seeded on discs measuring 10 mm in diameter and 2 mm in thickness. Cellular viability was evaluated by the @entity98 test for every stage of observation. An histological study to observe the invasion in the depth of discs was performed. Scanning electron microscopy was used to analyze the cellular comportment in contact with the surface of substitutes. RESULTS: An exponential cellular growth was effective on each substitute with the two cellular types. Cells spread on the surface of the compounds covering macropores and colonized the depth of the discs. A size of macropore of 300 microm or more seemed to support this invasion. 15 microm sized interconnections appeared to be effective to allow cell migration between macropores. The cell proliferation was similar on substitutes with or without microporosity. CONCLUSION: Biomaterials currently used as bone substitute are more or less osteoconductive but they have no osteoinductive property. A hybrid association of @entity78 ceramic with osteogenic cells should promote the development of a @entity78 compound with osteoinductive capacity.

title: [Cellular culture of osteoblasts and fibroblasts on porous XXXX - @entity1391 bone substitutes].

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: Cholinergic transmission plays a pivotal role in learning, memory and cognition, and disturbances of cholinergic transmission have been implicated in @entity16 including @entity195 , @entity302 and @entity161 . Pharmacological alleviation of these diseases by drugs including @entity30182 ( @entity18380 ), promising in animal models, often fails in @entity1 . We therefore compared the effects of @entity18380 on glutamatergic and GABAergic transmission in slices from @entity35 and @entity1 neocortex. We used @entity5402 (CCh; an established agonist at metabotropic muscarinic @entity934 ( @entity3451 ) receptors (mAChRs)) as a reference. Standard electrophysiological methods including intracellular and field potential recordings were used. In the @entity35 neocortex, @entity18380 prevented the CCh-induced decrease of GABAA and GABAB receptor-mediated responses but not the CCh-induced increase of the @entity308 . @entity18380 reduced neither the amplitude of the excitatory postsynaptic potentials (EPSP) nor antagonized the CCh-induced @entity308 of EPSP. In the @entity1 neocortex, however, @entity18380 failed to prevent CCh-induced decrease of the GABAB responses and directly reduced the amplitude of EPSP. These data suggest distinct effects of @entity18380 in @entity35 and @entity1 at M2 and M4 mAChRs underlying presynaptic modulation of @entity1246 and @entity3264 release, respectively. In particular, @entity18380 might be a M2 mAChR antagonist in the @entity35 but has no activity at this receptor in @entity1 neocortex. However, @entity18380 has an agonistic effect at M4 mAChR in the @entity1 but no such effect in the @entity35 neocortex. The present study confirms that pharmacology at mAChRs can differ between species and emphasizes the need of studies in @entity1 tissue.

title: Different pharmacology of XXXX at @entity1 and @entity35 M2 and M 4 mAChRs in neocortex.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['paired-pulse depression', 'depression']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorders']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease"]

entities_list: @entity30182 :: ('MESH:C058272', 'Chemical') :: ['N-desmethylclozapine']

entities_list: @entity5402 :: ('MESH:D002217', 'Chemical') :: ['carbachol']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity30182 :: (MESH:C058272,Chemical) :: ['N-desmethylclozapine']


abstract: Cholinergic transmission plays a pivotal role in learning, memory and cognition, and disturbances of cholinergic transmission have been implicated in @entity16 including @entity195 , @entity302 and @entity161 . Pharmacological alleviation of these diseases by drugs including @entity30182 ( @entity18380 ), promising in animal models, often fails in @entity1 . We therefore compared the effects of @entity18380 on glutamatergic and GABAergic transmission in slices from @entity35 and @entity1 neocortex. We used @entity5402 (CCh; an established agonist at metabotropic muscarinic @entity934 ( @entity3451 ) receptors (mAChRs)) as a reference. Standard electrophysiological methods including intracellular and field potential recordings were used. In the @entity35 neocortex, @entity18380 prevented the CCh-induced decrease of GABAA and GABAB receptor-mediated responses but not the CCh-induced increase of the @entity308 . @entity18380 reduced neither the amplitude of the excitatory postsynaptic potentials (EPSP) nor antagonized the CCh-induced @entity308 of EPSP. In the @entity1 neocortex, however, @entity18380 failed to prevent CCh-induced decrease of the GABAB responses and directly reduced the amplitude of EPSP. These data suggest distinct effects of @entity18380 in @entity35 and @entity1 at M2 and M4 mAChRs underlying presynaptic modulation of @entity1246 and @entity3264 release, respectively. In particular, @entity18380 might be a M2 mAChR antagonist in the @entity35 but has no activity at this receptor in @entity1 neocortex. However, @entity18380 has an agonistic effect at M4 mAChR in the @entity1 but no such effect in the @entity35 neocortex. The present study confirms that pharmacology at mAChRs can differ between species and emphasizes the need of studies in @entity1 tissue.

title: Different pharmacology of @entity30182 at @entity1 and XXXX M2 and M 4 mAChRs in neocortex.

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: Cholinergic transmission plays a pivotal role in learning, memory and cognition, and disturbances of cholinergic transmission have been implicated in @entity16 including @entity195 , @entity302 and @entity161 . Pharmacological alleviation of these diseases by drugs including @entity30182 ( @entity18380 ), promising in animal models, often fails in @entity1 . We therefore compared the effects of @entity18380 on glutamatergic and GABAergic transmission in slices from @entity35 and @entity1 neocortex. We used @entity5402 (CCh; an established agonist at metabotropic muscarinic @entity934 ( @entity3451 ) receptors (mAChRs)) as a reference. Standard electrophysiological methods including intracellular and field potential recordings were used. In the @entity35 neocortex, @entity18380 prevented the CCh-induced decrease of GABAA and GABAB receptor-mediated responses but not the CCh-induced increase of the @entity308 . @entity18380 reduced neither the amplitude of the excitatory postsynaptic potentials (EPSP) nor antagonized the CCh-induced @entity308 of EPSP. In the @entity1 neocortex, however, @entity18380 failed to prevent CCh-induced decrease of the GABAB responses and directly reduced the amplitude of EPSP. These data suggest distinct effects of @entity18380 in @entity35 and @entity1 at M2 and M4 mAChRs underlying presynaptic modulation of @entity1246 and @entity3264 release, respectively. In particular, @entity18380 might be a M2 mAChR antagonist in the @entity35 but has no activity at this receptor in @entity1 neocortex. However, @entity18380 has an agonistic effect at M4 mAChR in the @entity1 but no such effect in the @entity35 neocortex. The present study confirms that pharmacology at mAChRs can differ between species and emphasizes the need of studies in @entity1 tissue.

title: Different pharmacology of @entity30182 at XXXX and @entity35 M2 and M 4 mAChRs in neocortex.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: A retrospective analysis was performed to evaluate the prognostic significance of peritoneal cytology in @entity1 with @entity1204 limited to the uterus. A total of 280 @entity1 with surgically staged @entity1204 that was histologically confined to the uterus were examined clinicopathologically. The median length of follow-up was 62 (range, 12-135) months. All @entity1 underwent hysterectomy and salpingo-oophorectomy with selective lymphadenectomy, and only three @entity1 received adjuvant postoperative therapy. No preoperative adjuvant therapy was employed. In all, 48 @entity1 (17%) had positive peritoneal cytology. The 5-year survival rate among @entity1 with positive or negative peritoneal cytology was 91 or 95%, respectively, showing no significant difference (log-rank, P=0.42). The disease-free survival rate at 36 months was 90% among @entity1 with positive cytology, compared with that of 94% among @entity1 with negative cytology, and the difference was not significant (log-rank, P=0.52). Multivariate proportional hazards model revealed only histologic grade to be an independent prognostic factor of survival (P=0.0003, 95% CI 3.02 - 40.27) among the factors analysed (age, peritoneal cytology, and depth of @entity3 ). Multivariate analysis revealed that histologic grade (P=0.02, 95% CI 1.21-9.92) was also the only independent prognostic factor of disease-free survival. We concluded that the presence of positive peritoneal cytology is not an independent prognostic factor in @entity1 with @entity1204 confined to the uterus, and adjuvant therapy does not appear to be beneficial in these @entity1 .

title: Prognostic significance of positive peritoneal cytology in XXXX confined to the uterus.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['myometrial invasion']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['endometrial carcinoma']


abstract: Insulin-like growth factors (IGFs) I and II are potent mitogens for @entity0 cells. Their proliferative activity is likely to be influenced by their binding proteins (IGFBPs), a family of newly identified proteins. We report here on the in vivo hormonal regulation of mRNAs for @entity2620 and IGFBPs in the @entity7045 -induced @entity35 @entity5 , a well-established model of hormone-responsive mammary @entity5 . @entity2620 mRNA levels tended to decrease in regressing @entity5 following ovariectomy, and they markedly increased upon reactivation of @entity5 growth with hormone repletion. Ovariectomy induced a drastic increase in @entity2619 mRNA which was reversible with hormone repletion. Similar but more modest changes were observed with @entity7815 mRNA. In contrast, @entity9929 and @entity10777 mRNAs tended to decrease with ovariectomy and increase with hormone repletion. These latter effects, however, were modest, variable, and not statistically significant. In situ hybridization analysis revealed that @entity2620 , @entity10778 , and @entity2619 mRNAs were localized in the stromal component of the @entity5 , whereas @entity7815 mRNA was expressed by epithelial cells. We conclude that hormonal regulation of IGFBP expression is heterogeneous, thus suggesting divergent biological functions for these peptides. Our data also emphasize the importance of potential stromal-epithelial interactions in the control of @entity0 cell proliferation by IGFs.

title: Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by XXXX cells in vivo: evidence for stromal epithelial interactions.

entities_list: @entity7045 :: ('CHEBI:50102', 'Chemical') :: ['N-nitrosomethylurea']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'mammary tumor', 'tumors']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: The case of a young @entity1 aged 26 is reported. He presented with a short history of painful gynaecomastia, and no other associated symptoms. Radiological investigations showed a mass in the anterior mediastinum. Endocrine investigations showed high circulating @entity53 and high @entity7807 levels. There was no evidence of primary @entity5 or @entity3 . Surgical removal of the mediastinal mass led to normalization of @entity53 and @entity7807 levels and regression of gynaecomastia. Histology showed the @entity5 to be a primary @entity4797 staining positively for @entity7807 . Further treatment consisted of chemotherapy with @entity2879 and @entity900 . The @entity1 has remained well with no evidence of disease recurrence. The @entity5 markers remain normal.

title: Gynaecomastia caused by a primary XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['testicular tumour', 'tumour']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cis-platinum']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['oestradiol']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity4797 :: ('MESH:D018239', 'Disease') :: ['mediastinal seminoma']

answer: @entity4797 :: (MESH:D018239,Disease) :: ['mediastinal seminoma']


abstract: UNASSIGNED: @entity21384 (DP) is a chlorinated flame retardants that is globally ubiquitous. It is a potentially persistent organic pollutant (POPs) and an environmental toxin. However, the @entity137 data is still limited and cannot provide a comprehensive environmental ecological risk assessment for DP. In this study, luminous bacteria, Vicia faba and @entity14825 were chosen as testing organisms to investigate the acute @entity137 and mutagenicity of DP. The concentration gradient of DP used in this study was chosen based on its environmental levels (experiments of luminous bacteria: 0.591, 2.95, 14.8, 73.8, 369 gL(-1); micronucleus tests: 2.4, 12, 60, 300, 1500 gL(-1); comet assay: 2.4, 12, 60, 300, 1500 gL(-1)). For luminous bacteria, the relative luminosities were around 100% in treated groups, which suggested that there is no acute @entity137 to luminous bacteria under the studied DP concentrations. The micronucleus test showed no significant difference between treatment and control groups, indicating no genotoxicity of DP. However the comet assay conducted with @entity14825 was relatively sensitive as there was a significant increase in DNA damage when the concentrations of DP increased from 300 to 1500 gL(-1), while the lower concentrations failed to show any treatment-related differences. Therefore, DP may pose a potential risk at concentration   300 gL(-1). The results provide scientific information on the ecological risk assessment of DP.

title: Potential genotoxicity and risk assessment of a chlorinated flame retardant, XXXX .

entities_list: @entity21384 :: ('MESH:C526360', 'Chemical') :: ['Dechlorane Plus']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity14825 :: ('5911', 'Species') :: ['T. thermophila', 'Tetrahymena thermophila']

answer: @entity21384 :: (MESH:C526360,Chemical) :: ['Dechlorane Plus']


abstract: The pitch vertical vestibulo-ocular reflex (VOR) is accurate and symmetrical when tested in the normal upright posture, where otolith organ and central velocity storage signals supplement the basic VOR mediated by the semicircular canals. However, when the animal and @entity717 are together repositioned by rolling 90 degrees to one side, head forward pitch rotations that excite the anterior semicircular canals elicit a more accurately timed VOR than do oppositely directed rotations that excite the posterior canals. This suggests that velocity storage of posterior canal signals is lost when the head is placed on its side. We recorded from 47 VOR relay neurons, second-order vestibulo-ocular neurons, of alert @entity468 to test whether asymmetries are evident in the responses of neurons in the medial and superior vestibular nuclei during earth-horizontal @entity2270 rotations in the normal upright posture. Neurons were identified by antidromic responses to oculomotor nucleus stimulation and orthodromic responses to labyrinth stimulation, and were classified as having primarily anterior, posterior, or horizontal canal input based on response directionality. Neuronal response gains and phases were recorded during 0.5 Hz and 0.05 Hz @entity5501 in darkness. During 0.5 Hz rotations, anterior canal second-order vestibulo-ocular neurons responded approximately in phase with head velocity (mean phase re head position, +/- SE, 80 degrees +/- 3 degrees, n=18), as did posterior canal second-order vestibulo-ocular neurons (mean phase 81 degrees +/- 1 degree, n=25). Lowering the rotation frequency to 0.05 Hz resulted in only slight advances in response phases of individual anterior canal second-order vestibulo-ocular neurons (mean phase 86 degrees +/- 6 degrees, mean advance 7 degrees +/- 5 degrees, n=12). In contrast, posterior canal second-order vestibulo-ocular neurons behaved more like semicircular canal afferents, with responses markedly phase-advanced (mean advance 28 degrees +/- 5 degrees, n=14) by lowering rotation frequency to 0.05 Hz (mean phase 111 degrees +/- 5 degrees, n=14). In summary, low frequency responses of anterior and posterior canal second-order vestibulo-ocular neurons recorded during horizontal @entity2270 pitch correspond to the VOR they excite during vertical @entity2270 pitch. These results show that velocity storage is evident at anterior but not posterior canal second-order vestibulo-ocular neurons. We conclude that responses of posterior canal second-order vestibulo-ocular neurons are insufficient to explain the accurate low frequency VOR phase observed during backward head pitch in the upright posture, and that velocity storage or otolith signals required for VOR accuracy are carried by other neurons.

title: Timing of low frequency responses of anterior and posterior canal vestibulo-ocular neurons in alert XXXX .

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['rotation axis']

entities_list: @entity5501 :: ('MESH:D006504', 'Disease') :: ['sinusoidal oscillations']

answer: @entity468 :: (9685,Species) :: ['cats']


abstract: The objective of this study was to determine the need for repeat prostatic biopsies in @entity1 whose initial biopsy results revealed no evidence of @entity5 or atypia. We evaluated 1,136 @entity1 who underwent 1 or more prostatic biopsies in a longitudinal @entity1486 ( @entity1486 ) based @entity263 screening study that called for biopsy if the serum @entity1486 level was greater than 4.0 ng./ml. (Hybritech assay) and findings on rectal examination or ultrasonography were abnormal or suspicious for @entity5 . Of the 1,136 @entity1 who underwent prostatic biopsy 391 (34%) had @entity263 on the initial biopsy. Of 427 @entity1 who had negative initial biopsy results, a persistent serum @entity1486 level of greater than 4.0 ng./ml. and abnormal rectal or ultrasound examination findings 82 (19%) had @entity5 on biopsy 2. Of 203 @entity1 with persistent abnormalities 16 (8%) had @entity5 on biopsy 3 and 6 of 91 (7%) had @entity5 on biopsy 4 or later. Thus, 96% of the @entity5 were detected through either biopsy 1 or 2. The median initial @entity1486 level, followup @entity1486 levels and the yearly rate of change in @entity1486 were significantly greater in @entity1 whose @entity5 was detected compared with those of @entity1 whose @entity5 was not detected (6.4 versus 5.4 ng./ml., 7.4 versus 6.6 ng./ml. and 1.1 versus 0.7 ng./ml. per year, respectively). There was a trend for a higher percentage of @entity5 detected through serial screening to be pathologically organ confined with those detected through initial screening (73% versus 62%, p = 0.07). We conclude that @entity1 with a persistently elevated serum @entity1486 value after an initial negative prostatic biopsy should routinely undergo at least 1 repeat biopsy to exclude adequately the presence of detectable @entity263 .

title: Serial prostatic biopsies in @entity1 with persistently elevated serum XXXX values.

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'tumors']

entities_list: @entity1486 :: ('354', 'Gene') :: ['PSA', 'prostate specific antigen']

answer: @entity1486 :: (354,Gene) :: ['prostate specific antigen']


abstract: The objective of this study was to determine the need for repeat prostatic biopsies in @entity1 whose initial biopsy results revealed no evidence of @entity5 or atypia. We evaluated 1,136 @entity1 who underwent 1 or more prostatic biopsies in a longitudinal @entity1486 ( @entity1486 ) based @entity263 screening study that called for biopsy if the serum @entity1486 level was greater than 4.0 ng./ml. (Hybritech assay) and findings on rectal examination or ultrasonography were abnormal or suspicious for @entity5 . Of the 1,136 @entity1 who underwent prostatic biopsy 391 (34%) had @entity263 on the initial biopsy. Of 427 @entity1 who had negative initial biopsy results, a persistent serum @entity1486 level of greater than 4.0 ng./ml. and abnormal rectal or ultrasound examination findings 82 (19%) had @entity5 on biopsy 2. Of 203 @entity1 with persistent abnormalities 16 (8%) had @entity5 on biopsy 3 and 6 of 91 (7%) had @entity5 on biopsy 4 or later. Thus, 96% of the @entity5 were detected through either biopsy 1 or 2. The median initial @entity1486 level, followup @entity1486 levels and the yearly rate of change in @entity1486 were significantly greater in @entity1 whose @entity5 was detected compared with those of @entity1 whose @entity5 was not detected (6.4 versus 5.4 ng./ml., 7.4 versus 6.6 ng./ml. and 1.1 versus 0.7 ng./ml. per year, respectively). There was a trend for a higher percentage of @entity5 detected through serial screening to be pathologically organ confined with those detected through initial screening (73% versus 62%, p = 0.07). We conclude that @entity1 with a persistently elevated serum @entity1486 value after an initial negative prostatic biopsy should routinely undergo at least 1 repeat biopsy to exclude adequately the presence of detectable @entity263 .

title: Serial prostatic biopsies in XXXX with persistently elevated serum @entity1486 values.

answer: @entity1 :: (9606,Species) :: ['men']


abstract: OBJECTIVE: To report our experience with orthotopic liver transplantation (OLT) for highly selected @entity1 with @entity5 ( @entity157 ). DESIGN: We retrospectively analyzed the demographic, clinical, pathologic, and survival data on 21 @entity1 with @entity157 who underwent OLT at the Mayo Clinic between 1985 and 1993. MATERIAL AND METHODS: The 21 @entity1 were categorized into three groups: (1) those with incidental @entity157 (no evidence of @entity157 preoperatively), (2) those with a @entity99 without vascular invasion, and (3) those with an increased serum @entity160 ( @entity160 ) concentration but no detectable @entity66 in the liver. RESULTS: For the seven @entity1 with incidental @entity157 , the 2-year disease-free survival was 68.5%. For the eight @entity1 with a @entity66 , the 2-year disease-free survival was only 50%. Operative staging revealed more advanced stage disease than had been found on preoperative assessment in five of these eight @entity1 . For the six @entity1 with an increased serum @entity160 value but no @entity66 , the 2-year disease-free survival was 80%. @entity5 recurrence was the major cause of all deaths in this series. CONCLUSION: Disease-free survival for @entity1 with radiographic early-stage @entity157 was suboptimal because of understaging of the disease preoperatively. In contrast, our initial experience with OLT for @entity1 with an increased serum @entity160 value in the absence of a @entity66 in the liver was favorable.

title: Orthotopic liver transplantation for preoperative XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['mass lesion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['early-stage hepatocellular carcinoma', 'Tumor']

entities_list: @entity160 :: ('174', 'Gene') :: ['alpha-fetoprotein', 'AFP']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['unicentric hepatic lesion']

answer: @entity5 :: (MESH:D009369,Disease) :: ['early-stage hepatocellular carcinoma']


abstract: OBJECTIVES: The aims of this study were to evaluate the effect of left ventricular (LV) dysfunction on clinical outcomes after transcatheter aortic valve replacement (TAVR) and standard therapy for severe @entity472 ( @entity472 ) and to assess @entity1002 ( @entity1002 ) recovery and its impact on subsequent clinical outcomes. METHODS: Cohort B of the Placement of AoRtic TraNscathetER Valves trial randomised 342 inoperable @entity1 with severe @entity472 to TAVR or standard therapy. We defined @entity1002 as an @entity1002 <50% and @entity1002 improvement as an absolute increase in @entity1002 >= 10% at 30   days. RESULTS: Baseline @entity1002 did not affect survival after TAVR but was associated with increased cardiac mortality at 1 year with standard therapy (59.3% vs 45.8% with normal @entity1002 ; HR=1.71 (95% CI 1.08 to 2.71); p=0.02). In those with @entity1002 , @entity1002 improvement occurred in 48.7% and 30.4% of TAVR and standard therapy @entity1 , respectively (p=0.08), and was independently predicted by relative wall thickness and receipt of TAVR. @entity1002 improvement with standard therapy portended reduced all-cause mortality at 1   year (28.6% vs 65.6% without @entity1002 improvement; HR=0.32 (95% CI 0.11 to 0.93); p=0.03) but not at 2   years. CONCLUSIONS: In inoperable @entity1 with severe @entity472 , mild-to-moderate @entity1002 is associated with higher cardiac mortality with standard therapy but not TAVR. A subset of @entity1 undergoing standard therapy with @entity1002 demonstrates @entity1002 improvement and favourable 1-year but not 2-year survival. TAVR improves survival and should be considered the standard of care for inoperable @entity1 with @entity472 and @entity1002 >20%. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Unique Identifier #NCT00530894.

title: Transcatheter aortic valve replacement and standard therapy in inoperable @entity1 with XXXX and low EF.

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['AS', 'aortic stenosis']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['LVEF', 'LV dysfunction', 'LV ejection fraction']

answer: @entity472 :: (MESH:D001024,Disease) :: ['aortic stenosis']


abstract: OBJECTIVES: The aims of this study were to evaluate the effect of left ventricular (LV) dysfunction on clinical outcomes after transcatheter aortic valve replacement (TAVR) and standard therapy for severe @entity472 ( @entity472 ) and to assess @entity1002 ( @entity1002 ) recovery and its impact on subsequent clinical outcomes. METHODS: Cohort B of the Placement of AoRtic TraNscathetER Valves trial randomised 342 inoperable @entity1 with severe @entity472 to TAVR or standard therapy. We defined @entity1002 as an @entity1002 <50% and @entity1002 improvement as an absolute increase in @entity1002 >= 10% at 30   days. RESULTS: Baseline @entity1002 did not affect survival after TAVR but was associated with increased cardiac mortality at 1 year with standard therapy (59.3% vs 45.8% with normal @entity1002 ; HR=1.71 (95% CI 1.08 to 2.71); p=0.02). In those with @entity1002 , @entity1002 improvement occurred in 48.7% and 30.4% of TAVR and standard therapy @entity1 , respectively (p=0.08), and was independently predicted by relative wall thickness and receipt of TAVR. @entity1002 improvement with standard therapy portended reduced all-cause mortality at 1   year (28.6% vs 65.6% without @entity1002 improvement; HR=0.32 (95% CI 0.11 to 0.93); p=0.03) but not at 2   years. CONCLUSIONS: In inoperable @entity1 with severe @entity472 , mild-to-moderate @entity1002 is associated with higher cardiac mortality with standard therapy but not TAVR. A subset of @entity1 undergoing standard therapy with @entity1002 demonstrates @entity1002 improvement and favourable 1-year but not 2-year survival. TAVR improves survival and should be considered the standard of care for inoperable @entity1 with @entity472 and @entity1002 >20%. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Unique Identifier #NCT00530894.

title: Transcatheter aortic valve replacement and standard therapy in inoperable XXXX with @entity472 and low EF.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Pathologic @entity174 are associated with intractable @entity158 , loss of function and high morbidity in @entity1 with metastatic spine disease. However, the failure mechanisms of vertebrae with @entity154 and the failed vertebrae's ability to retain load carrying capacity remain unclear. METHODS: Eighteen @entity1 thoracic and lumbar vertebrae with simulated uncontained bone defects were tested under compression-bending loads to failure. Failure was defined as 50% reduction in vertebral body height. The vertebrae were allowed to recover under load and re-tested to failure using the initial criteria. Repeated measure ANOVA was used to test for changes in strength and stiffness parameters. FINDINGS: @entity177 occurred via buckling and @entity174 of the cortex around the defect, followed by collapse of the defect region. Compared to the intact vertebrae, the failed vertebrae exhibited a significant loss in compressive strength (59%, p<0.001), stiffness (53%, p<0.05) and flexion (70%, p<0.01) strength. Significant reduction in anterior-posterior shear (strength (63%, p<0.01) and stiffness (67%, p<0.01)) and lateral bending strength (134%, p<0.05) were similarly recorded. In the intact vertebrae, apart from flexion strength (r(2)=0.63), both compressive and anterior-posterior shear strengths were weakly correlated with their stiffness parameters (r(2)=0.24 and r(2)=0.31). By contrast, in the failed vertebrae, these parameters were strongly correlated, (r(2)=0.91, r(2)=0.86, and r(2)=0.92, p<0.001 respectively). INTERPRETATION: Failure of the vertebral cortex at the defect site dominated the initiation and progression of vertebral failure with the vertebrae failing via a consolidation process of the vertebral bone. Once failed, the vertebrae showed remarkable loss of load carrying capacity.

title: Effect of the metastatic defect on the structural response and failure process of XXXX vertebrae: An experimental study.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['lytic defects']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['vertebral fractures', 'fracture']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['Vertebral failure']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: We studied in 30 @entity1 with progressive or relapsing @entity1072 ( @entity1072 ) if hematopoietic stem cell transplantation (HSCT) after conditioning with @entity3118 , @entity1863 and ATG is effective and if treatment related mortality can be reduced compared to myeloablative conditioning regimens. @entity1 had 15 matched related and 15 matched unrelated donors. @entity2132 ( @entity2132 ) prophylaxis consisted of @entity205 alone or a combination with "short course" @entity1499 or @entity618 . The median follow-up is 24 months. At last follow up 11 @entity1 were in complete and 13 in partial remission. Six @entity1 had stable or progressive disease. Late complete remissions occurred up to one year after transplantation and the number of @entity1 with CR is still increasing. Four @entity1 died due to treatment related complications resulting in a probability of treatment-related mortality of 15% (CI 95%, 1% to 29%) at 2 years. The probability of overall survival and progression free survival at two years was 79% and 61%, respectively. In conclusion, HSCT after reduced conditioning may lower the treatment-related @entity137 and has the capacity to induce complete remissions.

title: Reduced non-relapse mortality after reduced intensity conditioning in advanced XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'Graft-versus-host disease']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil']

entities_list: @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

answer: @entity1072 :: (MESH:D015451,Disease) :: ['chronic lymphocytic leukemia']


abstract: UNASSIGNED: The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12  months in a group of @entity1 with proliferative @entity1988 from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with @entity1252 as defined by the American College of Rheumatology with biopsy-proven @entity1310 . We assessed 149 @entity1 , with 84  % female. Age at diagnosis of @entity1252 is 24.7  years (16-31). The time between diagnosis of @entity1252 and @entity1310 is 2  months (0-35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8  %), III (13.4  %), V   +   III (3.3  %), and V   +   IV (3.3  %). Activity index is 6.18        4.55 and chronicity index is 1 (0-3). The result of 24-h @entity644 is 2000  mg (667-4770) and baseline @entity1011 is 0.9  mg/dL (0.7-1.3). Induction therapy includes corticosteroids (100  %), @entity786 (74.1  %), and @entity618 (25.9  %). At 12  months, 40.7  % of individuals failed to attain partial or complete remission. Elevated @entity1011 (p   =   0.0001) and 24-h @entity644 greater than 1500  mg (p   =   0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline @entity1011 elevation (OR 3.62, 95  % CI, 1.59-8.23; p   =   0.002) and 24-h @entity644 greater than 1500  mg (OR 3.62, 95  % CI, 1.29-10.13; p   =   0.014) were independent predictors of failure to achieve partial or complete remission. At 12  months, 40.7  % of @entity1 did not attain partial or complete remission. Baseline elevated @entity1011 and 24-h @entity644 over 1500  mg were predictors for poor response.

title: Predictive factors for low rate of remission in a population of Colombian @entity1 with severe proliferative XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity1310 :: ('MESH:D009393', 'Disease') :: ['proliferative nephritis', 'nephritis']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus', 'lupus erythematosus']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity1988 :: (MESH:D008181,Disease) :: ['lupus nephritis']


abstract: UNASSIGNED: The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12  months in a group of @entity1 with proliferative @entity1988 from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with @entity1252 as defined by the American College of Rheumatology with biopsy-proven @entity1310 . We assessed 149 @entity1 , with 84  % female. Age at diagnosis of @entity1252 is 24.7  years (16-31). The time between diagnosis of @entity1252 and @entity1310 is 2  months (0-35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8  %), III (13.4  %), V   +   III (3.3  %), and V   +   IV (3.3  %). Activity index is 6.18        4.55 and chronicity index is 1 (0-3). The result of 24-h @entity644 is 2000  mg (667-4770) and baseline @entity1011 is 0.9  mg/dL (0.7-1.3). Induction therapy includes corticosteroids (100  %), @entity786 (74.1  %), and @entity618 (25.9  %). At 12  months, 40.7  % of individuals failed to attain partial or complete remission. Elevated @entity1011 (p   =   0.0001) and 24-h @entity644 greater than 1500  mg (p   =   0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline @entity1011 elevation (OR 3.62, 95  % CI, 1.59-8.23; p   =   0.002) and 24-h @entity644 greater than 1500  mg (OR 3.62, 95  % CI, 1.29-10.13; p   =   0.014) were independent predictors of failure to achieve partial or complete remission. At 12  months, 40.7  % of @entity1 did not attain partial or complete remission. Baseline elevated @entity1011 and 24-h @entity644 over 1500  mg were predictors for poor response.

title: Predictive factors for low rate of remission in a population of Colombian XXXX with severe proliferative @entity1988 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: Purpose To determine if a correlation exists between the number of previous enhanced magnetic resonance (MR) imaging examinations and high signal intensity in the globus pallidus (GP) and dentate nucleus (DN) in @entity1 who received @entity5777 ( @entity5777 ), a linear nonionic @entity2287 -based contrast agent, and in those who received @entity23432 (MultiHance), a linear ionic contrast agent. Materials and Methods Institutional review board approval was obtained for this single-center retrospective study, with waiver of informed consent. The study population included 69 @entity1 divided into two groups: Group 1 included @entity1 who underwent @entity5777 -enhanced MR imaging, and group 2 included @entity1 who underwent @entity23432 -enhanced MR imaging. Two radiologists conducted a quantitative analysis of unenhanced T1-weighted images by using region of interest measurements. The GP-to-thalamus (TH) signal intensity ratio, DN-to-middle cerebellar peduncle (MCP) signal intensity ratio and relative percentage change (Rchange) between the first and last examinations for each @entity1 were calculated. Relation between the signal intensity ratios and Rchange and the number of enhanced MR imaging examinations was analyzed by using a generalized additive model. Inter- and intraobserver agreement was evaluated with the Lin concordance correlation coefficient test. Results Group 1 included 23 @entity1 (19 female), with a mean of 5.0 doses    2.4 (standard deviation) (range, 3-11 doses) administered. Group 2 included 46 @entity1 (24 female) with a mean of 4.6 doses    2.2 (range, 3-11 doses) administered. The interval between the first and last examination was 1500.1 days    780.2 (range, 98-3097 days) for group 1 and 1086.2 days    582.9 (range, 94-2633) for group 2. All @entity1 had normal liver and renal function. @entity5777 showed a significant increase in DN:MCP and GP:TH (P < .001 for both) and in Rchange (P = .001 for GP:TH, P < .001 for DN:MCP). In group 2, there was no significant increase in DN:MCP or GP:TH over time or in Rchange for GP:TH, but there was a significant trend toward an increase in Rchange for DN:MCP (P = .013). Interobserver agreement was almost perfect (0.99; 95% confidence interval: 0.99, 0.99) for all evaluated structures. Intraobserver agreement was substantial to almost perfect for both readers. Conclusion A significant increase in GP:TH and DN:MCP is associated with multiple @entity5777 -enhanced studies but not with @entity23432 -enhanced studies, likely reflecting differences in stability and elimination of both contrast agents. Rate-of-change data indirectly suggest @entity2287 deposition in the DN with @entity23432 use, although it is considerably less than that with @entity5777 use. (  ) RSNA, 2015.

title: High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear XXXX -based Contrast Agents.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

entities_list: @entity23432 :: ('MESH:C064572', 'Chemical') :: ['gadobenate dimeglumine']

entities_list: @entity5777 :: ('MESH:C064925', 'Chemical') :: ['gadodiamide', 'Omniscan', 'Gadodiamide']

answer: @entity2287 :: (MESH:D005682,Chemical) :: ['Gadolinium']


abstract: INTRODUCTION: The major advances in neonatal intensive care have made less useful the Waterston's criteria for @entity1152 ( @entity1152 ) and/or @entity4501 ( @entity4501 ), and other prognostic classifications have been reported. The aim of this study was to determine the influence of various parameters on the outcome of @entity20434 . MATERIAL AND METHODS: We reviewed 97 cases admitted in our hospital for 29 years. We divided the cases in two groups in relation to the improvement of our neonatal unit care during the years: 1st. 1971-1982 (n = 46); 2nd. 1983-1999 (n = 51). chi 2 squared test and logistic regression analysis of the influence of several parameters before surgical treatment (Waterston's and Spitz's birth weight groups, @entity55 , @entity734 , severity of @entity154 and @entity299 ) on mortality was performed. RESULTS: The survival rate increased since 1983, reaching 86.2% in the last 10 years, although the number of neonates with birth weight < 1500 g has increased. Association with a @entity154 increased the mortality significantly in the 2nd. group only (45.5% major vs 7.1% minor and 8.3% none). The @entity299 were the most common, not only before 1983 (26.8%), but also since then (31.3%). When the neonate associated a major @entity299 the mortality was significantly higher in the 2nd. group (71.4%). The mortality, when @entity55 was present, was significantly higher before 1983 only (75% vs 32.4%), whereas the mortality was significantly increased by the need of ventilator in the 2nd. group only (85.7% vs 9.1%). Before 1983, the best prognostic parameters were the @entity55 and the severity of @entity154 , whereas only the @entity734 was selected between 1983 and 1999. CONCLUSIONS: The @entity20434 mortality has decreased in the last years. The associated @entity299 is the most common. We think that the @entity734 is the most reliable prognostic risk factor, showing a poor physiologic status of the neonate.

title: [Prognosis assessment of XXXX : our experience of 29 years].

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['major anomaly', 'associated anomalies']

entities_list: @entity4501 :: ('MESH:D014138', 'Disease') :: ['TEF', 'tracheoesophageal fistula']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity1152 :: ('MESH:D004933', 'Disease') :: ['esophageal atresia', 'EA']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac malformations', 'cardiac malformation']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['ventilator dependence']

answer: @entity1152 :: (MESH:D004933,Disease) :: ['esophageal atresia']


abstract: UNASSIGNED: This work presents an overview over heterogeneous photocatalysis performed in gas phase towards the degradation of @entity58465 , @entity1045 , @entity14143 , @entity37125 , @entity23940 and @entity7323 . The experimental set-up composed by a @entity702 plug flow reactor vessel contained a quartz tube with a 100 W UV lamp placed at center position from 1.7 cm to the quartz wall. A @entity6701 film was immobilized on the internal walls of the reactor and used as catalyst. All measurements were taken after reaching steady state condition and evaluated at the inlet and outlet of the system. Conversion rates were studied in a wide range of residence times yielding to a 90% or above conversion as from 20 seconds of residence time. During experiments the temperature of reactor's wall was monitored and remained between 52 and 62   C. Temperature influence over degradation rates was negligible once a control experiment performed at 15   C did not modify outgoing results. Humidity effect was also evaluated showing an ideal working range of 10 - 80% with abrupt conversion decay outside the range. By varying inlet concentration between 60 and 110 ppmv the VOC degradation curves remained unchanged. Loss over catalytic activity was only observed for @entity58465 after 30 minutes of reaction, the catalyst was reactivated with a solution of @entity273 and UV light followed by additional deposition of the catalytic layer. The kinetic study suggests a first order reaction rate. IMPLICATIONS: The study of effective and economically viable techniques on the treatment of volatile organic compounds (VOCs) has being highlighted as an important parameter on the environmental research. The heterogeneous photocatalysis in gas phase was proved to be an effective process for the degradation of the nonaromatic VOCs tested, yielding high conversion values for the optimized systems.

title: Degradation of volatile organic compounds in the gas phase by heterogeneous photocatalysis with XXXX /ultraviolet light.

entities_list: @entity7323 :: ('MESH:C045798', 'Chemical') :: ['2,2,4-trimethylpentane']

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['hydrogen peroxide']

entities_list: @entity6701 :: ('MESH:C009495', 'Chemical') :: ['titanium dioxide']

entities_list: @entity23940 :: ('MESH:C521475', 'Chemical') :: ['methylcyclohexane']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

answer: @entity6701 :: (MESH:C009495,Chemical) :: ['titanium dioxide']


abstract: @entity3570 causes @entity451 , @entity1241 , @entity1494 , @entity250 , @entity1276 and @entity853 in newborns. Its ethiology and pathogenesis are still not known, and probably multifactorial. AIM: To determine whether spinal cord exposition to the amniotic space causes a functional (impairment) and anatomic lesion similar to that of @entity1 @entity9960 . MATERIAL AND METHODS: Forty-eight fetal @entity95 underwent to create @entity3570 on the 23rd gestational day (term is 31 days). The procedure consisted of lumbosacral skin excision and posterior laminectomy. The fetuses are allowed to continue their gestation. On the 30th gestational by the operated fetuses were harvested, together with a group of nonoperated littermates for control. A clinical and neurologic evaluation was done, as well a study of somato-sensorial evoked potentials in the upper and lower limb and histologic study of the affected vertebral and cordial segment. RESULTS: The 26 surviving animals had @entity85 and lack of movement of the lower limbs. Evoked potentials showed absent response to stimuli in the lower limbs of animals with @entity3570 , whereas upper limbs and control animals did respond. Histologically the spinal cord of the operated @entity95 was uncovered and flattened. CONCLUSION: This model of @entity9960 in fetal @entity95 reproduces a variety of features similar to @entity1 @entity3570 , and hence can be used to study the pathophysiology of @entity3570 .

title: [Creation of a model for @entity9960 in XXXX embryos].

entities_list: @entity3570 :: ('MESH:D016135', 'Disease') :: ['spinal dysraphism', 'Spinal dysraphism', 'spina bifida']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['neurogenic bladder']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity853 :: ('MESH:D009139', 'Disease') :: ['skeletal abnormalities']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

entities_list: @entity9960 :: ('MESH:D008591', 'Disease') :: ['myelomeningocele']

entities_list: @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['deformity']

entities_list: @entity1241 :: ('MESH:D005242', 'Disease') :: ['fecal incontinence']

entities_list: @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual dysfunction']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: @entity3570 causes @entity451 , @entity1241 , @entity1494 , @entity250 , @entity1276 and @entity853 in newborns. Its ethiology and pathogenesis are still not known, and probably multifactorial. AIM: To determine whether spinal cord exposition to the amniotic space causes a functional (impairment) and anatomic lesion similar to that of @entity1 @entity9960 . MATERIAL AND METHODS: Forty-eight fetal @entity95 underwent to create @entity3570 on the 23rd gestational day (term is 31 days). The procedure consisted of lumbosacral skin excision and posterior laminectomy. The fetuses are allowed to continue their gestation. On the 30th gestational by the operated fetuses were harvested, together with a group of nonoperated littermates for control. A clinical and neurologic evaluation was done, as well a study of somato-sensorial evoked potentials in the upper and lower limb and histologic study of the affected vertebral and cordial segment. RESULTS: The 26 surviving animals had @entity85 and lack of movement of the lower limbs. Evoked potentials showed absent response to stimuli in the lower limbs of animals with @entity3570 , whereas upper limbs and control animals did respond. Histologically the spinal cord of the operated @entity95 was uncovered and flattened. CONCLUSION: This model of @entity9960 in fetal @entity95 reproduces a variety of features similar to @entity1 @entity3570 , and hence can be used to study the pathophysiology of @entity3570 .

title: [Creation of a model for XXXX in @entity95 embryos].

answer: @entity9960 :: (MESH:D008591,Disease) :: ['myelomeningocele']


abstract: PURPOSE: To analyse the rate of clinical recurrences in Brazilian @entity1 with @entity7375 after early high-dose corticosteroid treatment. METHODS: Retrospective study including @entity1 treated with early high-dose @entity288 ( @entity229 , 1-1.5  mg/kg/day, or 3-day 1  g @entity1667 pulsetherapy) within 1  month from disease onset followed by slow taper (at least 6  months). @entity1 with a minimum 12-month follow-up were subdivided based on the presence of disease recurrence or persistence after 6  months from initial presentation into: @entity697 ( @entity697 , no recurrences), chronic-recurrent (CR), and chronic-recurrent with @entity82 ( @entity82 ). Recurrences were defined as the presence of clinical and/or @entity941 angiography findings. RESULTS: Twenty-nine @entity1 (58 eyes) with a median follow-up of 65  months were included. Six (21  %), 11 (38  %) and 12 (41  %) @entity1 were allocated to @entity697 , CR, and @entity82 groups respectively. Though having received treatment within 1  month of onset, median time to initial treatment differed among groups (11, 15, and 25  days, in @entity697 , CR, and @entity82 groups respectively). Intensity of immunosuppression, @entity231 development, and longer time to achieve logMAR visual acuity  <=0.8 differed significantly among the groups, being more severe in @entity82 group. @entity1533 *0405 allele followed the same trend, though not reaching significance (0.5 in @entity697 group, 0.6 in CR, and 0.8 in @entity82 ). CONCLUSION: VKH disease in Brazilian @entity1 evolved to chronic-recurrent disease in 79  % of cases; 38  % developed @entity82 , in spite of similar initial treatment regimens. Time to initiate treatment influenced outcomes.

title: High rate of clinical recurrence in @entity1 with XXXX treated with early high-dose corticosteroids.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['AR', 'acute-resolved']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['SRF', 'subretinal fibrosis']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

entities_list: @entity7375 :: ('MESH:D014607', 'Disease') :: ['Vogt-Koyanagi-Harada (VKH) disease']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity7375 :: (MESH:D014607,Disease) :: ['Vogt-Koyanagi-Harada disease']


abstract: PURPOSE: To analyse the rate of clinical recurrences in Brazilian @entity1 with @entity7375 after early high-dose corticosteroid treatment. METHODS: Retrospective study including @entity1 treated with early high-dose @entity288 ( @entity229 , 1-1.5  mg/kg/day, or 3-day 1  g @entity1667 pulsetherapy) within 1  month from disease onset followed by slow taper (at least 6  months). @entity1 with a minimum 12-month follow-up were subdivided based on the presence of disease recurrence or persistence after 6  months from initial presentation into: @entity697 ( @entity697 , no recurrences), chronic-recurrent (CR), and chronic-recurrent with @entity82 ( @entity82 ). Recurrences were defined as the presence of clinical and/or @entity941 angiography findings. RESULTS: Twenty-nine @entity1 (58 eyes) with a median follow-up of 65  months were included. Six (21  %), 11 (38  %) and 12 (41  %) @entity1 were allocated to @entity697 , CR, and @entity82 groups respectively. Though having received treatment within 1  month of onset, median time to initial treatment differed among groups (11, 15, and 25  days, in @entity697 , CR, and @entity82 groups respectively). Intensity of immunosuppression, @entity231 development, and longer time to achieve logMAR visual acuity  <=0.8 differed significantly among the groups, being more severe in @entity82 group. @entity1533 *0405 allele followed the same trend, though not reaching significance (0.5 in @entity697 group, 0.6 in CR, and 0.8 in @entity82 ). CONCLUSION: VKH disease in Brazilian @entity1 evolved to chronic-recurrent disease in 79  % of cases; 38  % developed @entity82 , in spite of similar initial treatment regimens. Time to initiate treatment influenced outcomes.

title: High rate of clinical recurrence in XXXX with @entity7375 treated with early high-dose corticosteroids.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND AND AIMS: Symptoms compatible with irritable bowel syndrome (IBS) are common in @entity1 with @entity31 (UC) in clinical remission. It has been suggested that these symptoms might arise due to post-inflammatory changes comparable with post-infectious IBS. The aim was to study factors at new onset of UC that predict development of IBS-like symptoms during clinical remission. METHODS: In total, 98 @entity1 with new onset of UC were followed prospectively for 3 years with yearly follow-up visits. Data from the first visit at the onset of UC were compared between a group of @entity1 who fulfilled the criteria for IBS while in remission (UCR+IBS) during follow-up and a group who did not (UCR-IBS). RESULTS: Among the UC @entity1 , 87 met the criteria for clinical remission and 25 (29%) of these reported IBS-like symptoms in remission during follow-up. There was no difference in inflammatory disease activity at the initial flare or in the prevalence of previous IBS symptoms when comparing UCR+IBS and UCR-IBS @entity1 . The UCR+IBS @entity1 reported more severe @entity344 , including abdominal pain, during their primary flare. CONCLUSION: The severity and extent of inflammation at onset of UC do not seem to affect the development of IBS-like symptoms in UC @entity1 during clinical remission. The high prevalence of IBS-like symptoms is not explained by pre-existing IBS. UCR+IBS @entity1 reported more severe @entity344 at disease onset, which might indicate a more sensitive gastrointestinal tract in this category of @entity1 .

title: The severity of inflammation at onset of XXXX is not associated with IBS-like symptoms during clinical remission.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal symptoms']

answer: @entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']


abstract: UNASSIGNED: The origins and developmental regulation of cerebellar oligodendrocytes are largely unknown, although some hypotheses of embryonic origins have been suggested. Neural stem cells exist in the white matter of postnatal cerebellum, but it is unclear whether these neural stem cells generate oligodendrocytes at postnatal stages. We previously showed that cerebellar progenitor cells, including neural stem cells, widely express @entity1759 at around postnatal day 3. In the present study, we showed that @entity1759 -positive cells prepared from the postnatal day 3 cerebellum gave rise to neurospheres, while @entity1759 -negative cells prepared from the same cerebellum did not. These neurospheres differentiated mainly into oligodendrocytes and astrocytes, suggesting that @entity1759 -positive neural stem/progenitor cells might generate oligodendrocytes in postnatal cerebellum. We cultured @entity1759 -positive cells from the postnatal day 3 cerebellum in the presence of signaling molecules known as mitogens or inductive differentiation factors for oligodendrocyte progenitor cells. Of these, only @entity540 promoted survival and proliferation of @entity1759 -positive cells, and these cells differentiated into O4+ oligodendrocytes. Furthermore, we examined the effect of @entity540 on cerebellar oligodendrocyte development ex  vivo. @entity540 enhanced proliferation of oligodendrocyte progenitor cells and increased the number of O4+ and @entity14105 + oligodendrocytes in slice cultures. These results suggest that @entity1759 -positive cells might be a source of cerebellar oligodendrocytes and that @entity540 plays important roles in their development at an early postnatal stage.

title: XXXX signal promotes proliferation of cerebellar progenitor cells and their oligodendrocytic differentiation at early postnatal stage.

answer: @entity540 :: (2247,Gene) :: ['FGF-2']


abstract: BACKGROUND: Sex differences in @entity1187 ( @entity1187 ) have been well studied in major registries and clinical trials in Western populations. Limited studies have examined the sex differences in @entity1187 using a large number of Asian @entity1 as the subjects. OBJECTIVES: The aim was to study the sex differences in @entity1187 using the NCVD- @entity1187 (National @entity65 Database-Acute @entity301 ) registry. METHODS: We analyzed 13,591 @entity1187 @entity1 , of which 75.8% were @entity1 and 24.2% were @entity1 , from March 2006 to February 2010. Data were collected on demographic characteristics, risk factors, anthropometrics, treatments, procedures, mortalities, and complications. The results were compared among 3 cohorts of @entity1187 (ST-segment elevation @entity583 [STEMI], @entity583 , and @entity1459 ). RESULTS: @entity1 were older and more likely to have @entity6 , @entity101 , previous @entity712 , and cerebral vascular accidents than @entity1 were. @entity1 were less likely to receive in-hospital administration of @entity117 , beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and they were less likely to undergo angiography and percutaneous coronary intervention. In STEMI, a significantly lower proportion of @entity1 than @entity1 received primary percutaneous coronary intervention (6.2% vs. 6.7%, respectively, p  = 0.000) and fibrinolysis (64.4% vs. 74.6%, respectively, p  = 0.000). In addition, with regard to STEMI, @entity1 had a significantly higher unadjusted in-hospital mortality rate than @entity1 did (15.0% vs. 8.1%, respectively, p < 0.000). There was no statistically significant in-hospital mortality difference between sexes for @entity583 and @entity1459 . After adjustment for age and other covariates, a multivariate analysis showed no sex differences in the in-hospital mortality in all spectrums of @entity1187 . CONCLUSIONS: Our study showed significant sex differences in the demographic characteristics, risk factors, treatments, and outcomes of @entity1187 . More importantly, in @entity1187 @entity1 , we found evidence of suboptimal treatments and interventions in @entity1 versus @entity1 . Our findings provide an opportunity to narrow the sex gap in the care of @entity1 with @entity1187 in Malaysia.

title: Sex Differences in Acute @entity301 in a Multiethnic Asian Population: Results of the Malaysian National XXXX Database-Acute @entity301 (NCVD- @entity1187 ) Registry.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'men']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['Coronary Syndrome']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'non-STEMI']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular Disease']

answer: @entity65 :: (MESH:D002318,Disease) :: ['Cardiovascular Disease']


abstract: BACKGROUND: Sex differences in @entity1187 ( @entity1187 ) have been well studied in major registries and clinical trials in Western populations. Limited studies have examined the sex differences in @entity1187 using a large number of Asian @entity1 as the subjects. OBJECTIVES: The aim was to study the sex differences in @entity1187 using the NCVD- @entity1187 (National @entity65 Database-Acute @entity301 ) registry. METHODS: We analyzed 13,591 @entity1187 @entity1 , of which 75.8% were @entity1 and 24.2% were @entity1 , from March 2006 to February 2010. Data were collected on demographic characteristics, risk factors, anthropometrics, treatments, procedures, mortalities, and complications. The results were compared among 3 cohorts of @entity1187 (ST-segment elevation @entity583 [STEMI], @entity583 , and @entity1459 ). RESULTS: @entity1 were older and more likely to have @entity6 , @entity101 , previous @entity712 , and cerebral vascular accidents than @entity1 were. @entity1 were less likely to receive in-hospital administration of @entity117 , beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and they were less likely to undergo angiography and percutaneous coronary intervention. In STEMI, a significantly lower proportion of @entity1 than @entity1 received primary percutaneous coronary intervention (6.2% vs. 6.7%, respectively, p  = 0.000) and fibrinolysis (64.4% vs. 74.6%, respectively, p  = 0.000). In addition, with regard to STEMI, @entity1 had a significantly higher unadjusted in-hospital mortality rate than @entity1 did (15.0% vs. 8.1%, respectively, p < 0.000). There was no statistically significant in-hospital mortality difference between sexes for @entity583 and @entity1459 . After adjustment for age and other covariates, a multivariate analysis showed no sex differences in the in-hospital mortality in all spectrums of @entity1187 . CONCLUSIONS: Our study showed significant sex differences in the demographic characteristics, risk factors, treatments, and outcomes of @entity1187 . More importantly, in @entity1187 @entity1 , we found evidence of suboptimal treatments and interventions in @entity1 versus @entity1 . Our findings provide an opportunity to narrow the sex gap in the care of @entity1 with @entity1187 in Malaysia.

title: Sex Differences in Acute XXXX in a Multiethnic Asian Population: Results of the Malaysian National @entity65 Database-Acute @entity301 (NCVD- @entity1187 ) Registry.

answer: @entity301 :: (MESH:D003327,Disease) :: ['Coronary Syndrome']


abstract: BACKGROUND: Sex differences in @entity1187 ( @entity1187 ) have been well studied in major registries and clinical trials in Western populations. Limited studies have examined the sex differences in @entity1187 using a large number of Asian @entity1 as the subjects. OBJECTIVES: The aim was to study the sex differences in @entity1187 using the NCVD- @entity1187 (National @entity65 Database-Acute @entity301 ) registry. METHODS: We analyzed 13,591 @entity1187 @entity1 , of which 75.8% were @entity1 and 24.2% were @entity1 , from March 2006 to February 2010. Data were collected on demographic characteristics, risk factors, anthropometrics, treatments, procedures, mortalities, and complications. The results were compared among 3 cohorts of @entity1187 (ST-segment elevation @entity583 [STEMI], @entity583 , and @entity1459 ). RESULTS: @entity1 were older and more likely to have @entity6 , @entity101 , previous @entity712 , and cerebral vascular accidents than @entity1 were. @entity1 were less likely to receive in-hospital administration of @entity117 , beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and they were less likely to undergo angiography and percutaneous coronary intervention. In STEMI, a significantly lower proportion of @entity1 than @entity1 received primary percutaneous coronary intervention (6.2% vs. 6.7%, respectively, p  = 0.000) and fibrinolysis (64.4% vs. 74.6%, respectively, p  = 0.000). In addition, with regard to STEMI, @entity1 had a significantly higher unadjusted in-hospital mortality rate than @entity1 did (15.0% vs. 8.1%, respectively, p < 0.000). There was no statistically significant in-hospital mortality difference between sexes for @entity583 and @entity1459 . After adjustment for age and other covariates, a multivariate analysis showed no sex differences in the in-hospital mortality in all spectrums of @entity1187 . CONCLUSIONS: Our study showed significant sex differences in the demographic characteristics, risk factors, treatments, and outcomes of @entity1187 . More importantly, in @entity1187 @entity1 , we found evidence of suboptimal treatments and interventions in @entity1 versus @entity1 . Our findings provide an opportunity to narrow the sex gap in the care of @entity1 with @entity1187 in Malaysia.

title: Sex Differences in Acute @entity301 in a Multiethnic Asian Population: Results of the Malaysian National @entity65 Database-Acute XXXX (NCVD- @entity1187 ) Registry.

answer: @entity301 :: (MESH:D003327,Disease) :: ['Coronary Syndrome']


abstract: BACKGROUND: Sex differences in @entity1187 ( @entity1187 ) have been well studied in major registries and clinical trials in Western populations. Limited studies have examined the sex differences in @entity1187 using a large number of Asian @entity1 as the subjects. OBJECTIVES: The aim was to study the sex differences in @entity1187 using the NCVD- @entity1187 (National @entity65 Database-Acute @entity301 ) registry. METHODS: We analyzed 13,591 @entity1187 @entity1 , of which 75.8% were @entity1 and 24.2% were @entity1 , from March 2006 to February 2010. Data were collected on demographic characteristics, risk factors, anthropometrics, treatments, procedures, mortalities, and complications. The results were compared among 3 cohorts of @entity1187 (ST-segment elevation @entity583 [STEMI], @entity583 , and @entity1459 ). RESULTS: @entity1 were older and more likely to have @entity6 , @entity101 , previous @entity712 , and cerebral vascular accidents than @entity1 were. @entity1 were less likely to receive in-hospital administration of @entity117 , beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and they were less likely to undergo angiography and percutaneous coronary intervention. In STEMI, a significantly lower proportion of @entity1 than @entity1 received primary percutaneous coronary intervention (6.2% vs. 6.7%, respectively, p  = 0.000) and fibrinolysis (64.4% vs. 74.6%, respectively, p  = 0.000). In addition, with regard to STEMI, @entity1 had a significantly higher unadjusted in-hospital mortality rate than @entity1 did (15.0% vs. 8.1%, respectively, p < 0.000). There was no statistically significant in-hospital mortality difference between sexes for @entity583 and @entity1459 . After adjustment for age and other covariates, a multivariate analysis showed no sex differences in the in-hospital mortality in all spectrums of @entity1187 . CONCLUSIONS: Our study showed significant sex differences in the demographic characteristics, risk factors, treatments, and outcomes of @entity1187 . More importantly, in @entity1187 @entity1 , we found evidence of suboptimal treatments and interventions in @entity1 versus @entity1 . Our findings provide an opportunity to narrow the sex gap in the care of @entity1 with @entity1187 in Malaysia.

title: Sex Differences in Acute @entity301 in a Multiethnic Asian Population: Results of the Malaysian National @entity65 Database-Acute @entity301 (NCVD- XXXX ) Registry.

answer: @entity1187 :: (MESH:D054058,Disease) :: ['ACS']


abstract: INTRODUCTION: Air is commonly trapped within the skull in @entity1 who have been treated for @entity130 or @entity932 . In Sweden, when such a @entity1 is transported by air ambulance it is standard procedure to maintain sea-level pressure in the cabin to prevent @entity428 ( @entity428 ). However, this type of flight operation is more difficult and expensive. Maintenance of sea-level cabin pressure is not common practice all over the world, and the criteria supporting the choice of pressurization during transport are inadequate and in need of evaluation. The purpose of this study was to develop and evaluate a model to simulate the influence of intracranial air on @entity428 during air transport. METHODS: We identified an existing nonlinear model of the cerebral spinal fluid and @entity428 dynamics, then added intracranial air as a new component and evaluated the model through simulations. RESULTS: The model behaved as expected, and the simulations indicated that under normal flying conditions with decreased cabin pressure the initial intracranial air volume will increase by approximately 30% at normal maximum cabin altitude, 8000 ft. The increase in @entity428 depends upon both the initial air volume and the rate of change in cabin altitude. For an intracranial air volume of 30 ml the estimated worst-case increments of @entity428 from sea level to maximum altitude would be from 10 mm Hg to 21.0 mm Hg, or from 20 mm Hg to 31.8 mm Hg. DISCUSSION: Our results support the need for maintenance of sea-level pressure during air transport of @entity1 with suspected intracranial air, since an @entity428 increment could potentially impair the @entity1 's clinical condition.

title: Air transport of XXXX with intracranial air: computer model of pressure effects.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['ICP', 'increased intracranial pressure', 'intracranial pressure']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The aim of the study was to establish the benefit of an additional hypothetical laboratory criterion for @entity309 ( @entity309 ), comprising positivity for antikeratin antibody (AKA) and/or antiperinuclear factor (APF). The tests were applied to a series of 308 hospital @entity1 with various recent-onset @entity32 who were followed for 3 years. The performance of APF and AKA was compared with rheumatoid factor (RF). The most sensitive (.72) but the least specific (.86) test for @entity309 was the latex test. The most specific (.96) but the least sensitive (.33) test was AKA. Waaler-Rose and APF were intermediate. AKA and/or APF positive @entity1 had significantly more @entity2681 than @entity1 negative for these autoantibodies. Despite the impressive performance characteristics of APF and AKA, the actual classification impact achieved, as compared to using RF as the sole laboratory criterion, turned out to be moderate. This is because the criteria proved to be interrelated. Unlike RF, AKA and APF are not suited to the general laboratory, at least not in their present form. Moreover they so far lack the broad data base of RF.

title: Prospect for an additional laboratory criterion for XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory joint diseases']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: Rabbit antibodies were prepared against purified phospholipase A2 ( @entity10575 ) from @entity32766 ( @entity32766 ) venom. The PLA2 has haemolytic, @entity2359 , myotoxic, cytotoxic and @entity4 -inducing activities apart from the catalytic activity. The immunological cross-reactivity of structurally similar @entity2359 PLA2s was investigated using enzyme-linked immunosorbent assay (ELISA) and immunodiffusion. @entity1701 IgG cross-reacted with other purified @entity2359 PLA2s from the same venom. Immunochemical cross-reactions of anti- @entity10575 IgG with @entity10575 , NN-XIb-PLA2, NN-XIII-PLA2, NN-IVb1-PLA2 and NN-Vb-PLA2 were shown by a very high ELISA titre and a single precipitin band on double immunodiffusion agarose plates. The catalytic activity of these PLA2s was inhibited dose-dependently by anti- @entity10575 IgG but was unable to neutralize lethality and @entity2359 in experimental animals injected with @entity2359 PLA2. @entity1701 IgG fails to neutralize myotoxicity and @entity4 -inducing activities of @entity10575 and NN-XIII-PLA2. @entity1701 IgG inhibited cytotoxic effects of @entity10575 dose-dependently, but failed to inhibit NN-XIII-PLA2-induced @entity137 . Direct haemolytic activity of @entity10575 and NN-XIII-PLA2 was inhibited dose-dependently by these antibodies. The results indicate the presence of separate catalytic and pharmacologic site(s).

title: Immunochemical cross-reactivity of XXXX phospholipase A2 enzymes from @entity32766 ( @entity32766 ) venom using polyclonal antibodies.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity32766 :: ('35670', 'Species') :: ['Naja naja naja', 'Indian cobra']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxic', 'neurotoxic symptoms']

answer: @entity2359 :: (MESH:D020258,Disease) :: ['neurotoxic']


abstract: Rabbit antibodies were prepared against purified phospholipase A2 ( @entity10575 ) from @entity32766 ( @entity32766 ) venom. The PLA2 has haemolytic, @entity2359 , myotoxic, cytotoxic and @entity4 -inducing activities apart from the catalytic activity. The immunological cross-reactivity of structurally similar @entity2359 PLA2s was investigated using enzyme-linked immunosorbent assay (ELISA) and immunodiffusion. @entity1701 IgG cross-reacted with other purified @entity2359 PLA2s from the same venom. Immunochemical cross-reactions of anti- @entity10575 IgG with @entity10575 , NN-XIb-PLA2, NN-XIII-PLA2, NN-IVb1-PLA2 and NN-Vb-PLA2 were shown by a very high ELISA titre and a single precipitin band on double immunodiffusion agarose plates. The catalytic activity of these PLA2s was inhibited dose-dependently by anti- @entity10575 IgG but was unable to neutralize lethality and @entity2359 in experimental animals injected with @entity2359 PLA2. @entity1701 IgG fails to neutralize myotoxicity and @entity4 -inducing activities of @entity10575 and NN-XIII-PLA2. @entity1701 IgG inhibited cytotoxic effects of @entity10575 dose-dependently, but failed to inhibit NN-XIII-PLA2-induced @entity137 . Direct haemolytic activity of @entity10575 and NN-XIII-PLA2 was inhibited dose-dependently by these antibodies. The results indicate the presence of separate catalytic and pharmacologic site(s).

title: Immunochemical cross-reactivity of @entity2359 phospholipase A2 enzymes from XXXX ( @entity32766 ) venom using polyclonal antibodies.

answer: @entity32766 :: (35670,Species) :: ['Indian cobra']


abstract: Rabbit antibodies were prepared against purified phospholipase A2 ( @entity10575 ) from @entity32766 ( @entity32766 ) venom. The PLA2 has haemolytic, @entity2359 , myotoxic, cytotoxic and @entity4 -inducing activities apart from the catalytic activity. The immunological cross-reactivity of structurally similar @entity2359 PLA2s was investigated using enzyme-linked immunosorbent assay (ELISA) and immunodiffusion. @entity1701 IgG cross-reacted with other purified @entity2359 PLA2s from the same venom. Immunochemical cross-reactions of anti- @entity10575 IgG with @entity10575 , NN-XIb-PLA2, NN-XIII-PLA2, NN-IVb1-PLA2 and NN-Vb-PLA2 were shown by a very high ELISA titre and a single precipitin band on double immunodiffusion agarose plates. The catalytic activity of these PLA2s was inhibited dose-dependently by anti- @entity10575 IgG but was unable to neutralize lethality and @entity2359 in experimental animals injected with @entity2359 PLA2. @entity1701 IgG fails to neutralize myotoxicity and @entity4 -inducing activities of @entity10575 and NN-XIII-PLA2. @entity1701 IgG inhibited cytotoxic effects of @entity10575 dose-dependently, but failed to inhibit NN-XIII-PLA2-induced @entity137 . Direct haemolytic activity of @entity10575 and NN-XIII-PLA2 was inhibited dose-dependently by these antibodies. The results indicate the presence of separate catalytic and pharmacologic site(s).

title: Immunochemical cross-reactivity of @entity2359 phospholipase A2 enzymes from @entity32766 ( XXXX ) venom using polyclonal antibodies.

answer: @entity32766 :: (35670,Species) :: ['Naja naja naja']


abstract: An 83-year-old @entity1 was transferred to our cardiac intensive care unit with an acute non-Q-wave @entity583 and @entity3126 . Enoxaparin was one component of the treatment regimen used. Her hospital course was complicated by episodes of @entity551 , as well as by recurrent left hip and left thigh @entity158 . The defining event occurred when the @entity1 became acutely @entity551 and developed @entity1661 , peritoneal signs, intense @entity812 , and a 3.3 g/dl hemoglobin decrease. Abdominal computed tomography showed a 9 x 6 x 20 cm left retroperitoneal @entity1410 . The @entity1410 was spontaneous, secondary to enoxaparin use. The @entity1 died despite vigorous supportive care. @entity2120 is being increasingly used in @entity1 with @entity1187 . Review of the medical literature revealed that this is the first reported case of a @entity1 with an @entity1187 who died as a result of an @entity2120 -induced, @entity1410 . This article reviews important clinical signs and symptoms, identifies high-risk @entity1 populations, and discusses management strategies.

title: Fatal XXXX secondary to enoxaparin.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome', 'acute coronary syndromes']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal distention']

entities_list: @entity812 :: ('MESH:D021501', 'Disease') :: ['left flank pain']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['spontaneous retroperitoneal hematoma', 'hematoma']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive', 'hypotension']

entities_list: @entity2120 :: ('MESH:D017984', 'Chemical') :: ['enoxaparin', 'Enoxaparin']

answer: @entity1410 :: (MESH:D006406,Disease) :: ['spontaneous retroperitoneal hematoma']


abstract: INTRODUCTION: Defects in the lower two thirds of the face occur due to @entity130 , tumoral masses, or @entity281 . In this study, repairs of various defects located in the midface using facial artery perforator-based nasolabial flaps are presented. @entity1 AND METHODS: Between January 2009 and June 2013, 15 @entity1 with defects in the lower two thirds of the face or the intraoral region underwent repairs with facial artery perforator-based nasolabial flaps. The etiology was @entity1489 excisions in 11 @entity1 , @entity281 @entity1 , and @entity130 in 2 @entity1 . Among the @entity1 , 10 were male and 5 were female. Their mean age was 65.1 (range: 20-86) years. The mean duration of follow-up was 14 (7-24) months. The defects were located at the upper lip, cheek, lower lip, intraoral region, and the nasal area. The size of the defects varied between 10*10mm and 40*50mm. All the flaps were prepared as perforator flaps. The @entity1912 donor area was primarily closed. RESULTS: No partial or total @entity1912 loss was observed in any of the flaps. The @entity1912 donor areas healed without problem. Full @entity1 satisfaction was achieved both aesthetically and functionally. CONCLUSION: The nasolabial perforator @entity1912 has certain advantages such as the 1-stage application, repair using a similar tissue, a wider rotation arc around the pedicle compared to the other regional flaps, and the primary closure of the donor area. Based on these characteristics, it is an ideal alternative for the repairs of the defects located in the lower two thirds of the face or the intraoral region.

title: The Versatile Facial Artery Perforator-Based Nasolabial XXXX in Midface Reconstruction.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['malignant skin tumor']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection in 2', 'infections']

answer: @entity1912 :: (241,Gene) :: ['Flap']


abstract: To study the sand @entity238 fauna, surveys were performed at four different @entity232 sites in Ecuador from February 2013 to April 2014. A modified and simplified version of the conventional Shannon trap was named "mini-Shannon trap" and put to multiple uses at the different study sites in limited, forested and narrow spaces. The mini-Shannon, CDC light trap and protected @entity1 landing method were employed for sand @entity238 collection. The species identification of sand flies was performed mainly based on the morphology of spermathecae and cibarium, after dissection of fresh samples. In this study, therefore, only female samples were used for analysis. A total of 1,480 female sand flies belonging to 25 Lutzomyia species were collected. The number of female sand flies collected was 417 (28.2%) using the mini-Shannon trap, 259 (17.5%) using the CDC light trap and 804 (54.3%) by @entity1 landing. The total number of sand flies per trap collected by the different methods was markedly affected by the study site, probably because of the various composition of species at each locality. Furthermore, as an additional study, the attraction of sand flies to mini-Shannon traps powered with LED white-light and LED black-light was investigated preliminarily, together with the CDC light trap and @entity1 landing. As a result, a total of 426 sand flies of nine Lutzomyia species, including seven @entity1 -biting and two non-biting species, were collected during three capture trials in May and June 2014 in an area endemic for @entity232 (La Ventura). The black-light proved relatively superior to the white-light with regard to capture numbers, but no significant statistical difference was observed between the two traps.

title: Sand @entity238 fauna (Diptera, pcychodidae, phlebotominae) in different XXXX areas of ecuador, surveyed using a newly named mini-shannon trap.

entities_list: @entity232 :: ('MESH:D007896', 'Disease') :: ['leishmaniasis', 'leishmaniasis-endemic']

answer: @entity232 :: (MESH:D007896,Disease) :: ['leishmaniasis-endemic']


abstract: To study the sand @entity238 fauna, surveys were performed at four different @entity232 sites in Ecuador from February 2013 to April 2014. A modified and simplified version of the conventional Shannon trap was named "mini-Shannon trap" and put to multiple uses at the different study sites in limited, forested and narrow spaces. The mini-Shannon, CDC light trap and protected @entity1 landing method were employed for sand @entity238 collection. The species identification of sand flies was performed mainly based on the morphology of spermathecae and cibarium, after dissection of fresh samples. In this study, therefore, only female samples were used for analysis. A total of 1,480 female sand flies belonging to 25 Lutzomyia species were collected. The number of female sand flies collected was 417 (28.2%) using the mini-Shannon trap, 259 (17.5%) using the CDC light trap and 804 (54.3%) by @entity1 landing. The total number of sand flies per trap collected by the different methods was markedly affected by the study site, probably because of the various composition of species at each locality. Furthermore, as an additional study, the attraction of sand flies to mini-Shannon traps powered with LED white-light and LED black-light was investigated preliminarily, together with the CDC light trap and @entity1 landing. As a result, a total of 426 sand flies of nine Lutzomyia species, including seven @entity1 -biting and two non-biting species, were collected during three capture trials in May and June 2014 in an area endemic for @entity232 (La Ventura). The black-light proved relatively superior to the white-light with regard to capture numbers, but no significant statistical difference was observed between the two traps.

title: Sand XXXX fauna (Diptera, pcychodidae, phlebotominae) in different @entity232 areas of ecuador, surveyed using a newly named mini-shannon trap.

answer: @entity238 :: (7227,Species) :: ['fly']


abstract: Fourteen @entity4348 of the ovary with a prominent component of spindle-shaped epithelial cells are reported. Eleven were initially misdiagnosed as sexcord @entity5 , malignant mesodermal mixed @entity5 , @entity5 of probable wolffian origin, or metastatic @entity189 . All of the @entity5 , however, had one or more features establishing them as @entity4348 , including (a) glands typical of @entity4348 , (b) foci of squamous differentiation, and (c) an @entity2483 . Six cases were examined immunohistochemically, and the epithelial nature of the spindle cells was supported by immunostaining for keratin and epithelial membrane antigen. The @entity1 ranged in age from 42 to 89 years (mean, 61). Four cases were stage I, five stage II, and three stage III. Follow-up information was available in seven cases. Five @entity1 were free of disease at 8, 11, 32, 56, and 103 months, and two @entity1 were alive with disease at 10 and 20 months. The age of the @entity1 , clinical presentation, @entity5 stage, and gross appearance were similar to those of typical @entity4348 . It is important that this @entity5 be distinguished from other @entity43 with a spindle-cell component because of differences in treatment and prognosis.

title: XXXX with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian neoplasms']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stromal tumors', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity2483 :: ('MESH:C566443', 'Disease') :: ['adenofibromatous component']

entities_list: @entity4348 :: ('MESH:D018269', 'Disease') :: ['endometrioid adenocarcinoma', 'endometrioid carcinomas']

answer: @entity43 :: (MESH:D010051,Disease) :: ['Endometrioid carcinoma of the ovary']